BridgeBio Pharma is a clinical-stage biotechnology company designing transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. The company's pipeline includes infigratinib (FGFR-driven cholangiocarcinoma and other indications), acoramidis (ATTR-CM, approved 2024), and an achondroplasia therapy that has shown compelling growth and body-proportionality benefit in clinical data.
Q2 2026 earnings and pipeline update
Achondroplasia therapy clinical updates and regulatory planning
BridgeBio is turning to YouTube and partnerships with hip-hop and public-health voices for a new campaign aimed at raising awareness of ATTR-CM, the rare heart condition treated by its drug Attruby.
BridgeBio’s Attruby cruises toward blockbuster land
BridgeBio gets funding for drug launch; United buys into cell therapy (BioPharma Dive.)
BridgeBio Pharma highlights kidney-related benefits of its approved ATTR-CM drug Attruby, positioning the therapy to differentiate from competing amyloidosis treatments. (Source: BioSpace, 2026-07-06)
BridgeBio adds $1B as it prepares three more drug launches
Sixth Street, KKR invest up to $1B to propel BridgeBio launches. (Fierce Pharma.)
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer (Cardiometabolic)